Sugi Predict

Sugi Predict / Compounds / SCHEMBL6507050

SCHEMBL6507050

SCHEMBL6507050

CCOC(=O)C(C)(OCC)OCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 3/20 0.48
▸ CYP4A11 Q02928 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.43
▸ LMNA P02545 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ PKM P14618 3/20 0.41
▸ MMP8 P22894 2/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALOX15 P16050 1/20 0.40
▸ MGAM O43451 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ SI P14410 1/20 0.40
▸ MGAM2 Q2M2H8 1/20 0.40
▸ SOAT1 P35610 1/20 0.40
▸ THRB P10828 1/20 0.39
▸ ABCB11 O95342 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4174244 0.89 CYP4F2 (0.44) CYP4F2CYP4A11ALDH1A1LMNAHSD17B10
SCHEMBL13609677 0.80 CYP4F2 (0.44) CYP4F2CYP4A11ALDH1A1LMNAHSD17B10
SCHEMBL17358987 0.80 DGAT1 (0.39) CYP4F2CYP4A11ALDH1A1LMNAHSD17B10
SCHEMBL195662 0.80 CYP4F2 (0.56) CYP4F2CYP4A11ALDH1A1LMNAHSD17B10
SCHEMBL5469810 0.80 CYP4F2 (0.44) CYP4F2CYP4A11ALDH1A1LMNAHSD17B10
SCHEMBL11374293 0.79 CYP4F2 (0.51) CYP4F2CYP4A11ALDH1A1MEN1KMT2A
SCHEMBL8592528 0.79 TSHR (0.41) CYP4F2CYP4A11ALDH1A1HSD17B10PKM
SCHEMBL19331262 0.78 CYP4F2 (0.34) CYP4F2CYP4A11ALDH1A1ABCB11CYP1A2
SCHEMBL27665143 0.78 DGAT1 (0.43) CYP4F2CYP4A11ALDH1A1MEN1KMT2A
SCHEMBL15066109 0.78 CYP4F2 (0.38) CYP4F2CYP4A11ALDH1A1PKMTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590089-B2 Processes for preparing toll-like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2026-03-31 — — US disclosed
CN-119371422-A Methods for preparing Toll-like receptor modulator compounds 吉利德科学公司 2025-01-28 — — CN disclosed
CN-114269744-B Methods for preparing Toll-like receptor modulator compounds 吉利德科学公司 2024-10-18 — — CN disclosed
US-20240279152-A1 METHODS OF PRODUCING DIALKYL MALONATE ESTERS AND USES THEREOF CARGILL, INCORPORATED (US) 2024-08-22 — — US disclosed
CN-117940133-A Therapeutic agents for degradation of mutant BRAF C4医药公司 2024-04-26 — — CN disclosed
CN-114178292-B System and method for realizing co-production of various ester products by taking food waste as raw material 西安建筑科技大学 2023-06-06 — — CN disclosed
WO-2022251795-A1 METHODS OF PRODUCING DIALKYL MALONATE ESTERS AND USES THEREOF CARGILL, INCORPORATED (US) 2022-12-01 — — WO disclosed
US-20220274985-A1 PROCESSES FOR PREPARING TOLL-LIKE RECEPTOR MODULATOR COMPOUNDS GILEAD SCIENCES, INC. 2022-09-01 — — US disclosed
EP-3990455-A1 PROCESSES FOR PREPARING TOLL-LIKE RECEPTOR MODULATOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-05-04 — — EP disclosed
CN-114269744-A Methods for preparing Toll-like receptor modulator compounds 吉利德科学公司 2022-04-01 — — CN disclosed
CN-1152033-C Synthese of substitutd pyrazolopyrimidines Ŧ�޿���������ѧ��˾ 2004-06-02 — — CN disclosed
CN-1372561-A Synthesis of Substituted Pyrazolopyrimidines NEUROCRINE BIOSCIENCES INC (US) 2002-10-02 — — CN disclosed
EP-1208102-A1 SYNTHESIS OF SUBSTITUTED PYRAZOLOPYRIMIDINES Neurocrine Biosciences, Inc. (US) 2002-05-29 — — EP disclosed
US-6297250-B1 USEFUL FOR INHIBITING TRANSPORT OF NUCLEOSIDES OR PURINES ACROSS CELL MEMBRANES, THEREBY TO POTENTIATE THE ACTIVITY OF VARIOUS CYTOTOXIC ANTITUMOR DRUGS NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 2001-10-02 — — US disclosed
WO-2001010868-A1 SYNTHESIS OF SUBSTITUTED PYRAZOLOPYRIMIDINES NEUROCRINE BIOSCIENCES, INC. (US) 2001-02-15 — — WO disclosed
EP-0971925-A1 PYRIMIDOPYRIMIDINE COMPOUNDS NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 2000-01-19 — — EP disclosed
WO-1998043974-A1 PYRIMIDOPYRIMIDINE COMPOUNDS NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 1998-10-08 — — WO disclosed
WO-1998041557-A1 POLYESTER-BASED AMPHIPHILIC POLYMERS WITH CONDENSED ACETALIC GROUPS IN DETERGENTS AND CLEANING AGENTS KOCH, HERBERT 1998-09-24 — — WO disclosed
US-4304928-A 2-Alkoxyacrylate process CHEVRON RESEARCH COMPANY (US) 1981-12-08 — — US disclosed
US-4225589-A ANTITUMOR RHONE-POULENC INDUSTRIES (FR) 1980-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590089-B2 Processes for preparing toll-like receptor modulator compounds TLR8, MYD88, TLR6 CYP4F2 3375/4885CYP4A11 3432/4885ALDH1A1 3917/4885
US-20240279152-A1 METHODS OF PRODUCING DIALKYL MALONATE ESTERS AND USES THEREOF ME1, ME3, ME2 CYP4F2 885/4885CYP4A11 1350/4885ALDH1A1 178/4885
US-20220274985-A1 PROCESSES FOR PREPARING TOLL-LIKE RECEPTOR MODULATOR COMPOUNDS TLR4, TLR3, TLR6 CYP4F2 2408/4885CYP4A11 1631/4885ALDH1A1 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.